Surface Oncology, Inc.
SURF
|
$1.07
-0.93%
-1.41%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (68.1% 1y) (0.0% 2d) (-0.9% 3d) (0.0% 7d) (78.2% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 65,082,187
http://www.surfaceoncology.com
Sec Filling | Patents | 49 employees
(US) Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
cancer t-cell cd73 msa ceiling
add to watch list Paper trade email alert is off
Press-releases
Coherus Announces U.S. Launch of LOQTORZI™
Published: 2024-01-02 (Crawled : 13:30) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.0%
H: 11.11%
C: -5.71%
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -22.6%
H: 3.28%
C: -9.85%
business financial results
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2023-10-27 (Crawled : 19:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
| Email alert
Add to watchlist
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
| Email alert
Add to watchlist
fda approval treatment
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
Published: 2023-10-05 (Crawled : 12:30) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 2.52%
H: 7.08%
C: 6.77%
udenyca resubmission license application
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.19%
H: 0.59%
C: -6.49%
cimerli sales year
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
Published: 2023-10-02 (Crawled : 13:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -5.26%
day rare cancer designation
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-09-27 (Crawled : 13:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.75%
H: 2.0%
C: -1.0%
cancer immunotherapy meeting
Coherus Completes Surface Oncology Acquisition
Published: 2023-09-08 (Crawled : 13:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.23%
H: 2.63%
C: -1.21%
acquisition
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Published: 2023-08-31 (Crawled : 20:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.56%
H: 1.96%
C: 1.68%
glass
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.06%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 3.49%
H: 14.13%
C: 10.87%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 9.45%
H: 10.53%
C: 7.58%
business financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001209191-23-045496 | 4 | 2023-08-12 | 2023-08-01 | Sell | S | 3901 | 30899 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10